Search

Your search keyword '"Grabczewska Z"' showing total 47 results
Start Over Author "Grabczewska Z"
47 results on '"Grabczewska Z"'

2. Predicted and observed in-hospital mortality after left main coronary artery stenting in 204 patients

Author

Sukiennik, A., Ostrowska-Nowak, J., Wiśniewska-Szmyt, J., Radomski, M., Rychter, M., Jabłoński, M., Białoszyński, T., Koziński, M., Fabiszak, T., Dobosiewicz, R., Zabielska, E., Sukiennik, T., Kubica, A., Król, A., Demidowicz, K., Chojnicki, M., Grabczewska, Z., Światkiewicz, I., Bogdan, M., Grześk, G., and Jacek Kubica

Subjects
Adult, Aged, 80 and over, Male, Coronary Artery Disease, Middle Aged, Risk Assessment, Treatment Outcome, Predictive Value of Tests, Risk Factors, Humans, Female, Stents, Hospital Mortality, Angioplasty, Balloon, Coronary, Aged
Abstract

The purpose of this study was to compare risk predicted using available risk scores and actual outcomes in patients with left main coronary artery disease undergoing percutaneous coronary intervention with stent implantation (PCI LM).We studied 204 patients treated with elective or emergent coronary angioplasty. We estimated in-hospital mortality using the EuroSCORE, Parsonnet and GRACE risk scores and compared this data with actual in-hospital mortality.There were no deaths among 62 patients undergoing elective PCI LM regardless of the estimated risk. Acute coronary syndrome (ACS) was diagnosed in all 142 patients undergoing emergent PCI LM. Mortality in this group was 24% (34/142). Area under receiver operating characteristic curve (AUC) values for the EuroSCORE, Parsonnet and GRACE risk scores in patients with ACS were 0.812 (p = 0.0001), 0.857 (p = 0.0001), and 0.870 (p = 0.0001), respectively. No statistically significant differences were found when these AUC values for different evaluated risk scores were compared. Overall, the EuroSCORE and Parsonnet risk scores had no discriminative value, as all deaths occurred in the highest risk group. Only the GRACE risk score discriminated risk among intermediate- and high-risk patients with ACS.The EuroSCORE and Parsonnet scoring systems are of no value in predicting periprocedural mortality risk in patients undergoing elective PCI LM. Overall, discriminative ability of the EuroSCORE, Parsonnet, and GRACE risk scores in unselected patients with ACS undergoing emergent PCI LM was good. In this group of patients, the EuroSCORE and Parsonnet scoring systems had no discriminative value in low and moderate risk patients. Only the GRACE risk score discriminated risk among intermediate and high risk patients.

Published
2008

3. Intravenous NPA for the treatment of infarcting myocardium early; InTIME-II, a double-blind comparison of single-bolus lanoteplase vs accelerated alteplase for the treatment of patients with acute myocardial infarction

Author

Braunwald, E., Neuhaus, K. -L., Antman, E., Chew, P., Skene, A., Wilcox, R., Ambrosioni, E., Anderson, J., Apetrei, E., Bata, I., Carrageta, M., Col, J., Dalby, A., Davies, R., Deckers, J., Eichman, D., Grande, P., Greene, R., Gurfinkel, E., Heikkilä, J., Henry, T., Hillis, D., Hochman, J., Huber, K., Kostis, J., Klinke, P., López-Sendón, J., Mckendall, G., Móller, B., Moore, P., Morris, A., Mueller, H., Östör, E., Oto, A., Ruda, M., Sadowski, Z., Schweiger, M., Sequeira, R., Shah, P., Shannon, R., Smith, B., Sobel, B., Steingart, R., Tebbe, U., Toman, J., Traboulsi, M., Vahanian, A., Warnica, J. W., Willerson, J., Deitchman, D., Davidson, L., Folgia, T., Foxley, A., Goodman, J., Hauck, C., Henry, D., Mccabe, C., Pangerl, A., Thomson, A., Wagner, M., Kennedy, J. W., Cairns, J., Demets, D., Julian, D., Simoons, M., Charlesworth, A., Easton, J. D., Ferbert, A., Feske, S., Kuhn, P., Moseley, J., Rogg, J. M., Reichmann, H., Sloan, M., von Kummer, R., Zamani, A., Coulter, S., Giugliano, R., Skene, A. M., Ardill, R., Ince, Y., Peters, A., Ward, K., Wolf, L., Curtis, N., De Brés, J., Stead, S., Watson, S., Cutler, S., Friedman, J., Helfrick, R., Williams, S., Klimovsky, J., Kumagai, S., Adams, E., Anderson, C., Bauhuber, I., Bennett, L., Biro, E., Boyce, E., Bregman, B., Carvalho, P., Ciganovic, D., Csukas, M., Cuenca, P., De Cuyper, S., Diez, P., Dijkhuizen, M., Dille-Amo, C., Gonzalez-Santis, A., Gursoy, M., Hammarstrom, K., Harasta, E., Ingman, E., Kelemen, B., Keulen, I., Koren, A., Langthaler, G., Lemaire, F., Little, I., Montalban, C., Nijssen, K., Neumueller, I., Palander, M., Pekuri, T., Persson, U., Pilz, J., Oudotova, S., Pisklakov, V., Proinov, F., Ptaszynska, A., Read, J., Retei, S., Romeyer, F., Romanini, M., Saar, L., Salein, D., Samsonov, M., Simeon-Dubach, D., Simmonds, J., Skaza, M., Skvortsova, N., Smidlova, Z., Spitzerova, H., Strijdveen, I., Szajewski, T., Ugurnal, B., Valcarce, M., van Rompaey, I., Walker, A., Zak, E., Zimova, N., Barrero, C., Beck, E., Bruno, M. L., Caccavo, A., Cagide, A., Campo, A., Cermesoni, R., Chahin, M., Dutra, O., Estrada, J., Falu, E. A., Gagliardi, J., Garre, L. E., Liprandi, A. S., Luciardi, H., Mautner, B., Muntaner, J., Nau, G., Salzberg, S., Santopinto, J., Sinisi, A., Torres, H., Eber, B., Elliott, P., Hiemetsberger, H., Juhasz, M., Kühn, P., Leisch, F., Niktardjam, M., Reisinger, J., Schmalix, G., Schuster, R., Sihorsch, K., Silberhauer, K., Slany, J., Steinbach, K., Tragl, K. H., Valentin, A., Al Shwafi, K., Dasnoy, P., De Clippel, M., de Meester, A., De Raedt, H. J. L. P., Emonts, M., Evrard, P., Eycken, M., Geboers, M., Heyndrickx, G., Lauwers, K., Mitrie, K., Pirenne, B., Renard, M., Somers, Y., Timmermans, P., Van Kuyk, M., Van Mieghem, W., Vermeulen, J., Verrostte, J. M., Albuquerque, D., Ayoub, J. C. A., Carvalho, A., Cesar, L., Gebara, O., Golin, V., Knobel, E., Leaes, P., Neto, J. A. M., Nicolau, J. C., Piegas, L. S., Rabelo, A., Rassi, A., Sila, L., Simao, A. F., Ashton, T., Baillie, H., Bhargava, R., Bota, G., Cameron, W., Chan, N., Chan, Y. K., Daly, P. A., Darcel, I., Davies, E., Desjardin, L., Dhingra, S., Ducas, J., Ervin, F. L., Fortin, C., Fowlis, R., Fulop, J., Furey, M., Gagnon, S., Gebhardt, V., Giannaccro, P., Gosselin, G., Graham, J., Grondin, F., Heath, J. W., Henderson, M., Hilton, D. R., Hiscock, J., Hui, W., Kaza, L., Kesselman, T., Kouz, S., Kucerak, M., Lahoude, N., Lamothe, M., Lebouthillier, P., Lenis, J., Levesque, P., Lopez, J. F., Lubelsky, B., Macritchie, D., Mayer, J. -P., Mcdowell, J. D., Montigny, M., Orestien-Lyall, T., Parekh, P., Pistawka, K., Price, J. B., Pruneau, G., Quinn, B., Reid, B. R., Richmond, M., Rose, B., Schuld, R., Sharma, N. K., Shetty, P., Stanton, E., Strauss, H. D., Sussex, B., Theroux, P., Turabian, M., Turner, C., Vizel, S., Walker, M., Weeks, A., Winkler, L., Zacharias, G., Zimmerman, R., Bartolucci, J., Castro, P., Diaz, M. A., Illanes, G., Potthoff, S., Sanchez, E. C., Silva, L. M., Yovanovich, J., Zanetti, F. L., Alan, D., Balázová, K., Boček, P., Cerny, J., Fischerova, B., Holub, M., Hradec, J., Janota, T., Janský, P., Kasper, J., Klimsa, Z., Motovská, Z., Pleva, L., Pluhacek, L., Pšenčka, M., Semrád, B., Spinar, J., Staněk, V., Štípal, R., Suítil, P., Vítovec, J., Wichterie, D., Widimský, P., Zeman, K., Andersen, C. B., Kriegbaum, J., Nielsen, N., Nielsen, P. E., Schou, J. B., Teesalu, R., Voitk, J., Haapamäki, H. V. H., Halkosaari, M., Härkönen, M., Jägerholm, S., Kärjä-Koskenkari, P., Karthunen, P., Kesäniemi, Y. A., Koskivirta, H., Lehto, P., Lilja, M., Paakkinen, S., Palomäki, A. K., Pietilä, K., Tuominen, J., Viopio-Pulkki, L., Ylönen, H., Adi, I., Admant, P., Akadirik, A., Alagha, Z., Alhabaj, S., Amat, G., Andre, A. A., Apffel, F., Aswad, K., Baradat, G., Bareiss, P., Barthers, F. B., Baudet, M., Baudouy, M., Bearez, E. M., Berthou, J. D., Berzin, B., Bessede, G., Blanc, J. J., Bocara, A., Bonneau, A., Bourdad, C., Bouvier, J. M., Cassagnes, J., Cassat, A., Cazaux, P., Charbonnier, B., Clementy, J., Cohen, A., Coisne, D., Colin, P., Croizier, O., D’Hautefeuille, B., D’Ivernois, C., Daumas, P. L., Dauphin, C. L., Deforet, M. F., Degand, B., Dequeker, J. L., Dickele, M. C., Dugrand, P., Durand, S., Ebagosti, A., Elharrar, C., Equine, O., Fichter, E., Flork, L., Fouche, R., Fourchard, V., Fourme, T., Fournier, P. Y., Funck, F., Galley, D., Garbarz, E., Ghadban, W., Gladin, M., Grall, J. Y., Grand, A., Gryman, R., Guillard, N., Guillo, P., Haftel, Y., Hannebicque, G., Henry, R., Huret, J. F., Janin-Magnificat, L., Jarnier, J., Joly, A., Kamal, H., Khalife, A., Roynard, J. L., Lang, M., Lapeyssonnie, A., Ledain, L., Lejeune, P., Lemetayer, L., Lepori, R., Lombart, A., Lusson, J. R., Magnin, O., Marquand, A., Martelet, M. M., Martelli, A., Mathurin, C., Mentre, B., Messager, D., Morizot, M., Mouallem, M. J., Mouhoub, O., Mycimski, C., Nallet, O., Olive, T., Pacouret, G., Palcoux, M. C., Poulard, J. E., Pruvost, A., Quiret, J. C., Richard, C., Richard, P., Rickaud, P., Riehl-Aleil, V., Rifai, A., Rocher, R., Rotreff, P., Segrestin, B., Slama, M. S., Sultan, P., Tabone, X., Talbodec, A., Tissot, M. T., Toussaint, C., Veyrat, A., Zerrouk, Z., Adamczak, M., Altmann, E., Altybernd, B., Andreassen, G., Andresen, D., Appenrodt, H., Bachmann, S., Bäcker, U., Beckert, U., Behr, H. M., Beier, W., Beier, T., Berger, D., Bernsmeier, R., Beythien, R. D., Biechl, E., Biedermann, G., Bischoff, K. O., Blerich, J., Boch, H. B., Bonzel, T., Both, A. R., Breidenbach, K., Breuer, M., Breuer, H. W. M., Brunkhorst, F. B., Bruns, A., Bundschu, H. D., Burkhardt, W., Busse, H. J., Caesar, K., Cailloud, J., Chlosta, A., Chorlanopoulos, E., Consemüller, S., Decker, W., Dichgans, M., Dick, R., Diederich, K. W., Dienst, C., Dietz, A., Dißmann, R., Ditter, H., Doering, W., Drost, H., Dundalek, E. D., Eckardt, D., Edelmann, A., Eggeling, T., Eggert, G., Eichner, R., Endres, C., Engberding, R., Engel, H. J., Faehnrich, A., Fischer, J. L., Flor, A., Forycki, F. Z. F., Froböse, H. J., Fruehauf, T., Fuchs, M., Geiser, R., Geletneky, J., Gerdes, H., Gerecke, B., Gesing, S., Gieser, H., Girth, E., Glogner, P., Glover, M., Goetz, J., Goetz, H., Göttfert, G., Gottwik, M., Gregori, B., Grieshaber, M., Großmann, C., Gruber, G., Gunold, H., Häßler, W. H., Hackenjos, B., Hader, O., Hamer, H., Harmjanz, D., Hasst, G., Haun, H., Hauptmann, K. E., Hegge, F. J., Heinze, A., Heinze, R., Henrichs, K. J., Hergenröther, H., Herrmann, F., Herzig, C., Hey, D., Hill, S., Hinzmann, S., Hoffmann, S., Höfs, T., Höhler, H., Holle, G., Höltman, B. J., Horacek, T., Hossmann, V., Hübner, F. S., Hülskamp, C., Hunecke, R., Hust, M., Jaeckh, G., Jebens, C., Jennen, E., Jost, M., Justiz, R., Kallmann, L., Kalscheur, F., Kaschner, W., Kaspar, W., Kauder, E., Keitel, B., Keller, H., Kemkes, T., Kerler, N., Kester, M., Kettner, W., Kilp, M., Kirklies, A., Klaus, A., Klein, H. H., Klenböck, J. R., Kley, H. K., Klingenbeck, R., Koch, H., Kohler, B., Kohler, J., Kolloch, R., Konermann, M., Körber, H. G., Kother, T. K., Kötter, V., Kottwitz, B., Kozariszcsuk, G., Kracht, T., Kratzsch, G., Kreft, H. U., Kreuter, G., Krönert, H., Krönig, B., Krueger, E., Krülls-Münch, J., Kuckuk, H., Kuelschbach, M., Kuhrt-Lassay, O. W., Kummerhoff, P. W., Kunevt, R., Kurth, C. U., Lang, C., Lange, C., Langhoff, R., Laskus, A., Lazarus, P., Lehmann, H. U., Lenga, P., Lengfelder, W., Leupolz, W., Limbourg, P., Loos, U., Lucanus, W., Machill, K., Mäckel, P., Mackes, K. G., Maier, S., Makowski, B., Mandok, J., Manz, M., Mäurer, W., Meier, F., Meier, J., Menges, M., Merx, W., Meurers, G., Michels, U., Mickeler, C. H., Mons, D., Moos, E., Mueller, R., Müller, G., Nast, H. P., Naumann, G., Nebelsieck, H., Neubaur, J., Niederer, W., Nitsch, J., Noack, J., Nogai, K. F. W., Oberheiden, A., Obst, R., Ochs, H. R., Odemar, F., Odenthal, H. J. B., Offers, E., Öhl, S., Ohlmeier, H. A. R. M., Patzer, P., Pech, A., Peters, U., Petry, U., Pietschmann, G. J., Pistner, W., Plappert, B., Pohlmann, W. K., Pollock, B., Presser, H. J., Przytarski, K., Puerner, K. L., Raouf, N., Reike, N., Reil, G. H., Reinhard, U., Riebeling, V., Ritzmann, M., Rödder, J., Roth, E., Rüdelstein, R., Saborowski, F., Sauter, B., Sceffler, N., Schartl, A., Schifferdecker, E., Schlotterbeck, K. P., Schmidt, J., Schmidt-Dannert, D. R., Schmidt-Klewitz, H., Schmitz, H. J., Schnebelt, T., Schneider, H. L., Schneider, F. J., Schoeller, R., Scholz, D., Schoppe, W. D., Schreiner, G., Schroeder, J., Schuh, N., Schulte, K. L., Schulze, H., Schulze, H. D., Schuster, P., Schuster, H. P., Schweizer, P., Sechtem, U., Sedlmaier, H. P., Segel, S., Sehnert, W., Seidel, F., Siedentopf, K., Simon, H., Sodomann, C. P., Solbach, C., Sorges, E., Stabenow, S., Stadler, K. P., Stammwitz, E., Stein, U., Sternberg, H., Stiepak, C., Stockmann, M., Straus, W., Striegel, H., Struch, E., Strupp, G., Taubert, T. B. T., Thoeming, B., Thoß, A., Tinnappel, J., Tomsik, H., Topp, H., Troost, S., Öberreiter, A., Uebis, R., Ungler, T., Urbaszek, W., Vöhringer, H. F., von Arnim, T., von Leitner, E. R., von Löwis of Menar, A., von Mengden, H. J., von Smekal, P., Voss, W., Wacker, P., Warning, A., Warzecha, A., Wefers, U., Wehr, M., Weigel, H., Weissthanner, F., Weller, P., Werner, M., Wette, A., Wichert, H., Wielage, T., Wiese, U., Wilbrand, T. B., Wilhelms, E., Wilmsmann, G., Wolf, F. H., Wolf, T., Wonhas, F. C. M., Zastrow, B., Zeymer, U., Ziruler, S., Ziss, W., Zölch, K. A., Zwirner, K., Becker, D., Bosko, M., Csillag, I., Ermenyi, A., Fogas, J., Heltai, K., Jánosi, A., Katona, A., Kiraly, C., Kiss, B., Kutor, G., Mizik, R., Molnar, T., Mühl, M., Nagy, D., Palacti, I., Rudas, L., Sárosi, I., Simon, K., Sitkel, E., Sydó, T., Szaboki, F., Szikla, K., Szönyi, T., Timar, S., Vándor, L., Zamolyl, K., Walsh, M., Caspi, A., Swissa, M., Badano, L., Baldacci, G., Balli, E., Banda, D., Baretta, G., Boccalatte, A., Borgatti, M. L., Branzi, A., Burelli, C., Capelletti, D., Capucci, A., Caragiulo, D., Carbonieri, E., Cassin, M., Ceci, V., Cocchieri, M., Coletta, C., Conte, E., Contini, G. M., Corsini, G., D’Annunzio, E., De Blasi, M., De Luca, I., Delciterna, F., Di Pasquale, G., Diguardo, G., Fattore, L., Ferraiuulo, G., Finardi, A., Fioretti, P. M., Giunta, G., Guiducci, U., Guzzardi, G., Horando, G., Ignone, G., Lazzaroli, A., Levantesi, D., Liberati, R., Losi, E., Macor, F., Mangiameli, S., Martines, C., Meinardi, F., Morgera, T., Morozzi, L., Mostacci, M., Naccarella, F. F., Ottani, F., Palamara, A., Pani, A., Paperini, L., Pes, R., Pesola, A., Porzio, A., Raviele, A., Ricci, S., Rosi, A., Rossi, R., Rotiroti, D., Rusconi, L., Sabino, G., Saccone, V., Sanna, A., Scaramuzzino, G., Scorcu, G. P., Semprini, F., Severini, D., Staniscia, D., Tantalo, L., Tartagni, F., Terrosu, P., Tondelli, S., Trichero, R., Uslenghi, E., Vajola, S. F., Vetrano, A., Violi, E., Zardini, P., Zingarini, G. L., Zobbi, G., Zuin, G., Kalnins, U., Cârvekülg, A., Laanoca, J., Iacis, J., Lankiene, L., Laucevicius, A., Lukoseviciute, A., Palsauskaite, R., Petrauskiene, B., Soopóld, W., Uuetoa, H., Vilks, J., Vitonyte, R., Zakke, I., Dorantes, J., Hernández, H., Jerjes, C., Leva Garza, J. L., Martinez, C., Anneveldt, A., Baars, H. F., Baldew, S. C., Bendermacher, P. E. F., Boersma, L. V. A., Bos, R. J., Breedveld, R. W., Bruggink, P. W. F., Ciampricotti, R., Darmanata, J. I., de Porto, A. E., de Weerd, G. J., Deckers, J. W., Freericks, M. P., Hillebrand, F. A., Kerker, J. P., Koenen, J. C., Kofflard, M. G. M., Liem, K. L., Liem, A. H., Linssen, G. C. M., Lionarons, R. J., Peters, J. R. M., Posma, J. P., Saat, E. W. M., Savalle, L. H., Smits, W. C. G., Suttorp, M. J., Tans, A. C., Troquay, R. P. Th., van Beek, G. J., van Boven, A. J., Van der Heijden, R., Van Hessen, A., van Langeveld, R. A. M., van Lier, T. A. R., van Loo, L. W. H., van Wijngaarden, J., van Ziejl, L. G. P. M., Veerhoek, M. J., Vermer, F., Werner, H. A., Graven, T., Klykken, B., Meyerdieks, O., Omland, T. M., Otterstad, J. E., Pedersen, T., Rød, R., Banaszewski, M., Bednarkiewicz, Z., Bojarski, G., Ceremuzyñski, L., Czestochowska, E., Gajewski, M., Galewicz, M., Gorski, J., Grabczewska, Z. S., Gruchaka, M., Janicki, K., Janion, M., Jaworska, K., Jezewska, M., Kakol, J., Kizciuk, M., Kleinrok, A., Kolodziej, P., Komorowski, P., Konopka, A., Kopaczewski, J., Korecki, J., Kornacewicz-Jach, Z., Kowalewski, M., Kratochwil, D., Krolczyk, J., Krzminska-Pakula, M., Kurek, P., Kurowski, M., Kurpesa, M., Kurzawski, J., Kwiecien, R., Lenartowski, L., Lewandowski, M., Loboz-Grudzieñ, K., Luczak, G., Maliñski, A., Michalski, M., Musial, W., Nartowicz, E., Nowicka, A., Odyniec, A., Pasyk, S., Prastowski, W., Przybylski, A., Raczynska, A., Rodzik, J., Romanowski, M., Rynkiewicz, A., Rzyman, M., Sidorowicz, A., Sledziona, M., Sobiczewski, W., Sobkowicz, B., Sobolewska, J., Sokalski, L., Stepinska, J., Sterlinski, M., Stopinski, M., Świątecka, G., Szpernal, Z., Tarnowska, H., Trzos, E., Ujda, M., Wierzchowiecki, M., Wodynska, T., Wojciechowski, D., Wrabec, K., Wrzesinski, K., Zuk, P., Albuquergue, A., Costa, A., Cunha, D., Ferreira, D., Ferreira, R., Gaog Leiria, J. M., Pimenta, A., Rufino, E., Vasconcelos, J., Aldica, M., Balanescu, S., Bruckner, I. V., Capalneanu, R., Florescu, N., Georgescu, C. S., Cherasim, L., Ginshina, C., Merenta, A., Parvu, O., Radutiu, S., Savulescu, I., Vita, I., Averkov, O., Bokarev, I. N., Gratsiansky, N., Grigoriev, Y., Gruzdev, A., Kakhnovsky, I., Kheevehuk, T. V., Khrustalev, O., Kobalava, Y., Konoratieva, T. B., Koukline, Vladimir, Martiouchov, S., Pavlikova, E., Poskotinov, I., Rogalev, K., Sinopainikov, A., Syrkin, A., Tereschenko, S. T., Yavelov, I., Zavolghin, S., Čurilla, E., Kohn, R., Kovář, F., Murín, J., Poliačik, P., Drinovec, I., Horvat, M., Krivec, B., Markež, J., Pareznik, R., Pehnec, Z., Resman, J., Sifrer, F., Skale, R., Trinkaus, D., Voga, G., Baig, M. M. E., Blomerus, P., Botha, B. P., Burgess, L., Duncan, D., Duncan, D. I., Gillmer, D., Govender, N., Jardine, R. J., Kok, A., Manga, P., Naidu, R. K., Rajput, M. C., Ranjith, N., Roos, J. S., Snyders, F. A., Steingo, L., Stern, A., Tayob, F. Z., Vythilingum, S., Alonso-Orcajo, N., Arribas Jimenez, A., Ayestaran, J. I., Balsera, B. B. G., Barras, C., Castro, A., Cobo, N., Duque, A., Garcia, M. J., Goiriena, P., Gonzalez-Valdayo, M., Gulias Lopez, J. M., Jimenez Gomez, P., Lopez Garanda, V., Martín Santos, F., Nogueira, R., Pabon Osuna, P., Ponce De Leon, E., Quesada Dorador, A., Paya Serrano, R., Rodriguez, L., Rodriguez, M., Rubio, F., Ruiz-Salmeron, R., Solar, J., Toquero, J., Velasco, J., Vilar Herrero, V., Vizcaino, M., Wancisidor, X., Basilier, E., Birgersdotter, V., Björnsdotter, E., Bjurman, A., Hagström, D., Hallin, I., Hansen, O., Hemmingson, L. O., Lundkvist, L., Lycksell, M., Möller, B., Nolgard, P., Sjölund, G., Stjerna, A., Angehrn, W., de Benedetti, E., Diethelm, M., Gallino, A., Plebani, G., Vögelin, H. P., Wojtyna, W., Akgöz, H., Akgün, G., Akyürek, O., Batur, M. K., Bayata, S., Deger, N., Emel, O., Gürgün, C., Korkmaz, M. E., Kozan, O., Kumbasar, D., Muderrisoglu, H., Nisanci, Y., Ozin, B., Ozsaruhan, O., Payzin, S., Postaci, N., Sozcuer, H., Tamci, B., Topuzoglu, F., Türkoglu, C., Tutar, E., Ulucam, M., Ulusoy, T., Umman, B., Yalçinkaya, S., Yesil, M., Zoghi, M., Adams, P. C., Ahir, S., Ahsan, A. J., Akhtar, J., Albers, C. J., Al-Khafaji, M. N., Anderson, N., Bailey, R. J., Bain, R. J. I., Basu, A., Beal, A., Boyle, R. M., Brown, N., Campbell, S., Card, D., Cross, S. J., Davies, P., Davis, E. T. L., Dean, J. W., Deaner, A., Devine, M. A., Dhawan, J., Doig, J. C., Dubrey, S., Dunn, P. G., Dwight, J., Ecob, R., Fitzpatrick, H., Fletcher, S., Francis, C. M., Gershlick, A. H., Glennon, P. E., Goodfield, N. E., Grabau, W. J., Gray, M., Gray, K. E., Heath, J., Hendry, W. G., Highland, J., Hogg, K., Irving, J. B., James, M. A., Jennings, K., Joy, M., Kadr, H. H., Kahn, S., Keeling, P. J., Keir, P. M., Kemp, T. M., Kinaird, J., Kinsey, C., Knowles, K., Kooner, J. S., Lahiri, A., Lawson, C., Lewis, R., Macdermott, A. F. N., Mackay, A., Macleod, D. C., Mccance, A. J., Morrison, A., Mortimer, M., Mulvey, D., Murphy, J. J., Murray, S., Muthusamy, R., Myers, A., Nicolson, V. G., Northridge, D., Odemuyiwa, S., Oldroyd, K. G., Oliver, R. M., Pell, A. C. H., Pohl, J. E. F., Price, B., Quereshi, N., Rae, A. P., Reader, S., Reid, D. S., Reynolds, G. W., Robinson, A., Robson, R. H., Rodger, J. C., Rodrigues, E., Rose, E. L., Rowlands, D. B., Rowley, J. M., Rozkovec, A., Shreeve, J., Siklos, P., Smith, R. H., Sneddon, J. F., Somasundram, U., Squire, I., Stephens, J. D., Stephens-Lloyd, A., Strand, J. M., Stuart, J., Sutaria, N., Swan, J., Tait, G. W., Thomas, R. D., Thompson, M. A., Tildesley, G., Travill, C. M., Treadgold, J. A., Trelawney, J. M. S., Turner, D., Vallance, B. D., Wallbridge, D., Weissberg, P. L., White, E., Wicks, M., Wilcox, R. G., Wilkinson, P., Wiltshire, J. E., Wright, A., Andrea, B., Attassi, K., Bahr, R., Banas, J., Baran, K., Belknap, M., Bensman, M., Bertolet, B., Besley, D., Bethala, V., Betzu, R., Bhalla, R., Bhargava, M., Binder, A., Birkhead, R., Bodine, K., Brewer, D., Carey, S., Chengot, M., Coppola, J., Cragg, D., D’Arcy, B., Denny, D. M., Dilorenzo, P., Dixon, E., Doorey, A., Doty, D., Doty, W., Drossner, M., Eisenberg, P., Falco, T., Feldman, R., Freman, I., Frey, M., Garcia, J., Glassman, J., Goldman, S., Gomez, M., Gonzalez, M., Goodfield, P., Gottlieb, S., Grech, D., Hack, T., Haffey, T., Hanson, J., Havranek, E., Hermany, P., Hernandez, H., Herron, R., Hession, W., Hines, J., Hundley, R., Jacobs, W. C., Jerjes-Sanchez, C., Jerome, S., Josephson, R., Kalan, J., Kawalsky, D., Khan, A., Kmetzo, K., Kraemer, M., Lader, E., Landis, J., Lash, J., Leber, R., Leimbach, W., Leiva Garza, J. -L., Maddox, W., Magorien, R., Mahapatra, S., Mantecon, I., Mendelson, R., Miklin, J., Milas, J., Miller, R., Molk, B., Monrad, E. S., Morrison, J., Morse, H., Neustel, M., Nichols, D., Niederman, A., Nygaard, T., O’Connor, R., O’Riordan, W., Obermueller, S., Palmeri, S., Patel, R., Paul, T., Phiambolis, T., Piana, R., Polansky, B., Polinski, W., Ponce, G., Ribeiro, P., Roccario, E., Rogers, C. P., Rogers, W., Rosenblatt, A., Runyon, J. P., Scheel, F., Schmidt, P., Schneider, R., Schwartz, H., Shelhamer, L., Sheridan, F., Shine, W., Shook, T., Siskind, S., Slama, R., Spear, E., Stouffer, G., Strunk, B., Thadani, U., Timmis, G., Trautloff, R., Tse, A., Wohl, B., Zarren, H., Zucker, R., Kuster, F., and Pardie, J. P.

Subjects
Male, Risk, Infusions, medicine.medical_treatment, Myocardial Infarction, Bolus lytic therapy, Acute myocardial infarction, Tissue plasminogen activator, Thrombolytic drug, Double-Blind Method, Fibrinolytic Agents, medicine, Humans, Thrombolytic Therapy, Myocardial infarction, Infusions, Intravenous, Stroke, Aged, business.industry, ST elevation, Lanoteplase, Emergency department, Middle Aged, medicine.disease, Survival Analysis, Regimen, Relative risk, Anesthesia, Tissue Plasminogen Activator, Female, Intracranial Hemorrhages, Cardiology and Cardiovascular Medicine, business, Intravenous, medicine.drug
Abstract

AIMS To compare the efficacy and safety of lanoteplase, a single-bolus thrombolytic drug derived from alteplase tissue plasminogen activator, with the established accelerated alteplase regimen in patients presenting within 6 h of onset of ST elevation acute myocardial infarction. METHODS AND RESULTS 15,078 patients were recruited from 855 hospitals worldwide and randomized in a 2:1 ratio to receive either lanoteplase 120 KU. kg(-1)as a single intravenous bolus, or up to 100 mg accelerated alteplase given over 90 min. The primary end-point was all-cause mortality at 30 days and the hypothesis was that the two treatments would be equivalent. By 30 days, 6.61% of alteplase-treated patients and 6.75% lanoteplase-treated patients had died (relative risk 1.02). Total stroke occurred in 1.53% alteplase- and 1.87% lanoteplase-treated patients (ns); haemorrhagic stroke rates were 0.64% alteplase and 1.12% lanoteplase (P=0.004). The net clinical deficit of 30-day death or non-fatal disabling stroke was 7.0% and 7.2%, respectively. By 6 months, 8.8% of alteplase-treated patients and 8.7% of lanoteplase-treated patients had died. CONCLUSION Single-bolus weight-adjusted lanoteplase is an effective thrombolytic agent, equivalent to alteplase in terms of its impact on survival and with a comparable risk-benefit profile. The single-bolus regimen should shorten symptoms to treatment times and be especially convenient for emergency department or out-of-hospital administration.

Published
2000

20. Value of oral glucose tolerance test in the acute phase of myocardial infarction

Author

Grabczewska Zofia, Bronisz Marek, Kubica Aldona, Sukiennik Adam, Swiatkiewicz Iwona, Gierach Joanna, Fabiszak Tomasz, Magielski Przemyslaw, Kozinski Marek, Bronisz Agata, Sinkiewicz Anna, Junik Roman, and Kubica Jacek

Subjects
Diseases of the circulatory (Cardiovascular) system, RC666-701
Abstract

Abstract Background Although European guidelines advise oral glucose tolerance test (OGTT) in patients with acute myocardial infarction (AMI) before or shortly after hospital discharge, data supporting this recommendation are inconclusive. We aimed to analyze whether disturbances in glucose metabolism diagnosed before hospital discharge in AMI patients represents a latent pre-existing condition or rather temporary finding. Additionally, we planned to investigate the value of pre-selected glycemic control parameters as predictors of long-term glucometabolic state. Methods We assessed admission glycemia, glycated hemoglobin, mean blood glucose concentration on days 1 and 2 in 200 patients with a first AMI but without overt disturbances of glucose metabolism. We also performed OGTT at discharge and 3 months after discharge. Results The prevalence of disturbances in glucose metabolism (as assessed by OGTT) at 3 months was significantly lower than at discharge (29% vs. 48%, p = 0.0001). Disturbances in glucose metabolism were not confirmed in 63% of patients with impaired glucose tolerance and in 36% of patients with diabetes mellitus diagnosed during the acute phase of AMI. Age >77 years, glucose ≥12.06 mmol/l at 120 minutes during OGTT before discharge and mean blood glucose level on day 2 >7.5 mmol/l were identified as independent predictors of disturbances in glucose metabolism at the 3-month follow-up. Conclusions Disturbances in glucose metabolism observed in patients with a first AMI are predominantly transient. Elderly age, high plasma glucose concentration at 120 minutes during OGTT at discharge and elevated mean blood glucose level on day 2 were associated with sustained disturbances in glucose metabolism.

Published
2011
Full Text
View/download PDF

22. [Soluble selectins in myocardial infarction].

Author

Lampka M, Grabczewska Z, Krajewska M, Piskorska E, Hołyńska-Iwan I, and Kubica J

Subjects
Biomarkers blood, Female, Humans, Leukocyte Count, Leukocytes metabolism, Male, Middle Aged, Myocardial Infarction blood, Selectins blood
Abstract

Unlabelled: In myocardial infarction, the endothelial activation which induces leukocytes migration into the myocardial tissues, may play an important role in ischemic injury. Selectins, shedding from the surface of activated cells into bloodstream, maybe suggested as markers of endothelial activation and leukocytes stimulation. The aim of the study was evaluation. To evaluate serum soluble E- and P-selectin levels as endothelial activation marker and serum soluble L-selectin level as leukocytes stimulation marker in myocardial infarction., Material and Methods: We examined 27 patients with acute myocardial infarction (AMI) The control group (K) consisted of 23 healthy subjects without symptoms of coronary artery disease. The concentration of soluble selectins (sE-, sP-, sL-selectin) were analyzed in venous blood serum. Results of routine laboratory tests: lipid levels, leukocyte count, prothrombin time were also included into statistical analysis., Results: A significant decrease in serum sL-selectin level was observed in patients with acute myocardial infarction compared to the control group. However, no difference was found in sE- and sP-selectin levels between the patient group and the control group. The sE-selectin level correlated positively with triglicerides level and inversely with HDL cholesterol level. There were a positive correlation between sP-selectin level and leukocyte count as well as inverse correlation between sP-selectin level and prothrombin time. The sL-selectin level correlated positively with leukocyte count. There were also a positive correlation between sP-selectin level and sE-selectin as well as sL-selectin levels., Conclusions: The sE-selectin level increases with the severity of atherogenic changes in serum lipid profil, and sP-selectin level increases due to inflammatory and prothrombotic processes. The sL-selectin level is influenced by inflamamatory processes in the vascular wall. The sE- and sP-selectin levels, unchanged compared to the control group, do not reflect adequately the degree of endothelial activation. An decreased sL-selectin level may indicate functional depletion of leukocytes in patients with myocardial infarction and make it difficult to assess the degree of leukocytes stimulation.

Published
2013

23. Diurnal variation in platelet inhibition by clopidogrel.

Author

Kozinski M, Bielis L, Wisniewska-Szmyt J, Boinska J, Stolarek W, Marciniak A, Kubica A, Grabczewska Z, Navarese EP, Andreotti F, Siller-Matula JM, Rosc D, and Kubica J

Subjects
Adenosine Diphosphate metabolism, Aged, Blood Platelets metabolism, Clopidogrel, Female, Humans, Male, Middle Aged, Myocardial Infarction drug therapy, Myocardial Infarction physiopathology, Platelet Aggregation drug effects, Platelet Aggregation Inhibitors therapeutic use, Ticlopidine pharmacology, Ticlopidine therapeutic use, Blood Platelets drug effects, Circadian Rhythm drug effects, Platelet Aggregation Inhibitors pharmacology, Ticlopidine analogs & derivatives
Abstract

Morning increase in the occurrence of myocardial infarction, stroke and sudden cardiac death is a well-recognized phenomenon, which is in line with a morning enhancement of platelet aggregation. We investigated whether platelet inhibition during clopidogrel and aspirin therapy varies during the day. Fifty-nine consecutive patients (45 men and 14 women) with first ST-segment elevation myocardial infarction (STEMI) treated with primary percutaneous coronary interventions (pPCI) on dual antiplatelet therapy were prospectively enrolled into the study. Blood samples were collected 4 days after start of clopidogrel treatment at 6.00 a.m., 10.00 a.m., 2.00 p.m. and 7.00 p.m. Arachidonic acid and adenosine diphosphate (ADP)-induced platelet aggregation were assessed by impedance aggregometry. Platelet inhibition by clopidogrel was lowest in the midmorning: median ADP-induced platelet aggregation was 55%, 17% and 27% higher at 10.00 a.m. compared to 6.00 a.m., 2.00 p.m. and 7.00 p.m., respectively (p < 0.002). Nonresponsiveness to clopidogrel defined according to the device manufacturer was 2.4-fold more frequent in the midmorning than in the early morning. We observed a more pronounced midmorning increase in ADP-induced platelet aggregation in diabetic patients when compared to non-diabetics. In contrast, no diurnal variation in the antiplatelet effect of aspirin was observed. In conclusion, in patients presenting with STEMI undergoing pPCI, platelet inhibition by clopidogrel is less strong in the midmorning hours. This periodicity in platelet aggregation in patients on dual antiplatelet therapy should be taken into consideration when assessing platelet function in clinical studies.

Published
2011
Full Text
View/download PDF

24. [ECG changes in patients with stroke].

Author

Grabczewska Z, Swiatkiewicz I, and Kubica J

Subjects
Carotid Artery Thrombosis complications, Humans, Male, Middle Aged, Stroke diagnosis, Electrocardiography, Myocardial Ischemia diagnosis, Myocardial Ischemia etiology, Stroke complications
Abstract

We present a case of a male patient who was admitted to the cardiology department with a diagnosis of NSTEMI (deep negative T waves in all precordial leads). Two weeks earlier he was hospitalised because of a stroke caused by thrombosis of the left carotid artery. He had no angina. An ECHO showed a normal myocardial contractility of the left ventricle. The concentration of troponin I was also normal. No coronary artery stenosis was revealed in coronary angiography. We present a review of studies devoted to ECG changes in patients with stroke.

Published
2009

25. Gender differences and in-hospital mortality in patients undergoing percutaneous coronary interventions.

Author

Nowakowska-Arendt A, Grabczewska Z, Koziński M, Sukiennik A, Swiatkiewicz I, Grześk G, Radomski M, Bogdan M, Kochman W, and Kubica J

Subjects
Adult, Aged, Angina Pectoris mortality, Coronary Artery Disease therapy, Female, Humans, Male, Middle Aged, Myocardial Infarction mortality, Poland epidemiology, Retrospective Studies, Risk Assessment, Risk Factors, Sex Distribution, Women's Health, Angioplasty, Balloon, Coronary statistics & numerical data, Coronary Artery Disease mortality, Hospital Mortality
Abstract

Background: Many observational and randomised studies have suggested that women are referred for invasive diagnostics and treatment of coronary artery disease (CAD) less frequently than men, and the effects of percutaneous coronary intervention (PCI) among women are worse than in men., Aim: To compare direct results of PCI in men and women., Methods: The study was a retrospective assessment of case records of one thousand consecutive patients treated with PCI because of acute myocardial infarction (AMI) (344 patients), unstable angina (UA) (164 patients) and stable angina (SA) (492 patients). We examined the effects of demographic, angiographic and clinical variables on the duration of hospitalisation and in-hospital mortality separately in men and in women., Results: Women constituted 30.7% of patients treated with PCI because of AMI, 39.6% of those with UA and just 25.8% of those with SA. Women were significantly older than men, had a higher BMI, and more often suffered from hypertension and diabetes. The duration of hospitalisation was the same in men and women if the reason for PCI was SA or UA, however, in case of AMI women were hospitalised significantly longer than men. In the univariate analysis gender had no influence on in-hospital mortality regardless of the reason for PCI treatment. Among the variables subjected to multivariate analysis female gender, age, BMI, diabetes, hypercholesterolaemia, indication for PCI, final TIMI flow in the target vessel and cardiogenic shock as a complication of AMI were shown to affect mortality. Significant effects on in-hospital mortality for women were exhibited only by cardiogenic shock. Among men, indication for PCI, age, diabetes and final TIMI flow in the target vessel also had a significant influence on in-hospital mortality., Conclusions: Stable angina is a reason for performing PCI more rarely in women than in men. Women with CAD are older than men and have more risk factors. The in-hospital mortality among patients treated with PCI because of SA is independent of gender. Cardiogenic shock appeared to be the only factor that influences in-hospital mortality in women. In the case of men such an influence is also observed for indication for PCI (AMI, UA or SA), diabetes and final TIMI flow in the target vessel.

Published
2008

26. The effect of trimetazidine added to maximal anti-ischemic therapy in patients with advanced coronary artery disease.

Author

Grabczewska Z, Białoszyński T, Szymański P, Sukiennik A, Swiatkiewicz I, Koziński M, Kochman W, Grześk G, and Kubica J

Subjects
Aged, Angina Pectoris diagnosis, Angina Pectoris drug therapy, Coronary Angiography, Dose-Response Relationship, Drug, Drug Administration Schedule, Drug Therapy, Combination, Electrocardiography, Exercise Test, Exercise Tolerance drug effects, Female, Follow-Up Studies, Humans, Male, Middle Aged, Probability, Prospective Studies, Risk Assessment, Severity of Illness Index, Statistics, Nonparametric, Time Factors, Treatment Outcome, Coronary Disease diagnosis, Coronary Disease drug therapy, Exercise Tolerance physiology, Trimetazidine administration & dosage, Vasodilator Agents administration & dosage
Abstract

Background: The purpose of the study was to assess the effect of trimetazidine administered for 20 days in 56 patients with ischemic heart disease treated with maximal tolerated doses of anti-ischemic drugs who were not candidates for percutaneous or surgical revascularization., Methods: The efficacy of trimetazidine was evaluated by comparing exercise testing parameters before and after treatment, combined with the patient response to a questionnaire administered at baseline and following the treatment. We evaluated the duration of exercise, workload, double product, time to the occurrence of ischemic changes in ECG, the number of leads with diagnostic ST segment depression, and the magnitude of ST segment depression., Results: After 20 days of trimetazidine treatment, an improvement in exercise testing parameters was seen in about 50% of patients, and the differences of the mean values were statistically significant. The patient response to the questionnaire administered following the treatment indicated a decreased frequency of anginal episodes and an increased exercise duration to the occurrence of angina in two thirds of patients, less requirement for nitrates in 40% of patients, and increased exercise tolerance in 50% of patients. In patients with subjective response to treatment, comparison of exercise testing parameters before and after treatment showed significant increase in the duration of exercise, time to ischemic changes in ECG, and the degree of ST segment depression during peak exercise. In patients with no subjective response to treatment, a statistically significant difference was seen in the double product only., Conclusions: After 20 days of treatment with trimetazidine added to maximal anti-ischemic treatment in patients with refractory angina, an improvement in exercise testing parameters and subjective response to treatment were seen in about 40% of patients. In patients with subjective response to treatment, exercise testing parameters improved significantly compared to the baseline values.

Published
2008

27. Increased morning ADP-dependent platelet aggregation persists despite dual antiplatelet therapy in patients with first ST-segment elevation myocardial infarction: Preliminary report.

Author

Koziński M, Bielis L, Wiśniewska-Szmyt J, Sukiennik A, Grabczewska Z, Swiatkiewicz I, Ziołkowski M, Rość D, and Kubica J

Subjects
Abciximab, Aged, Antibodies, Monoclonal administration & dosage, Antibodies, Monoclonal therapeutic use, Anticoagulants administration & dosage, Anticoagulants therapeutic use, Clopidogrel, Dose-Response Relationship, Drug, Drug Administration Routes, Drug Therapy, Combination, Female, Follow-Up Studies, Heparin administration & dosage, Heparin therapeutic use, Humans, Immunoglobulin Fab Fragments administration & dosage, Immunoglobulin Fab Fragments therapeutic use, Male, Middle Aged, Myocardial Infarction blood, Myocardial Infarction physiopathology, Platelet Aggregation Inhibitors administration & dosage, Platelet Glycoprotein GPIIb-IIIa Complex antagonists & inhibitors, Ticlopidine administration & dosage, Ticlopidine analogs & derivatives, Ticlopidine therapeutic use, Treatment Outcome, Circadian Rhythm physiology, Electrocardiography, Myocardial Infarction drug therapy, Platelet Aggregation drug effects, Platelet Aggregation Inhibitors therapeutic use
Abstract

Background: Numerous trials have reported on the morning increase in the occurrence of myocardial infarction, stroke and sudden cardiac death. Similarly, enhanced morning platelet aggregation has been observed in healthy individuals and in subjects with coronary artery disease without adequate antiplatelet treatment. The purpose of the study was to assess circadian variation in platelet aggregation in patients with first ST-elevation myocardial infarction (STEMI) treated with primary percutaneous coronary interventions (pPCI) and dual antiplatelet therapy., Methods: Fifteen consecutive patients (12 men and 3 women) were prospectively recruited into the study. Blood samples were collected at 6.00 a.m., 10.00 a.m., 2.00 p.m. and 7.00 p.m. on the third day of hospitalization. Aggregation in response to arachidonic acid and adenosine diphosphate (ADP) was assessed in the whole blood on a new generation impedance aggregometer., Results: A morning increase of 75% in ADP-dependent platelet aggregation was noted in the study population (p < 0.04). In contrast, we failed to show any significant diurnal variation in arachidonic acid-mediated platelet aggregation. The magnitude of the morning surge in platelet aggregation after ADP stimulation did not correlate with its baseline level., Conclusions: Increased morning ADP-dependent platelet aggregation persists despite dual antiplatelet therapy in patients with first STEMI undergoing pPCI. The clinical significance of this finding remains to be demonstrated.

Published
2008

28. In search of understanding the endothelium.

Author

Grabczewska Z and Kubica J

Subjects
Case-Control Studies, Female, Humans, Hyperlipidemias complications, Male, Microvascular Angina complications, Reference Values, Sensitivity and Specificity, Vascular Resistance, Vasodilation physiology, Endothelium, Vascular physiopathology, Hyperlipidemias diagnosis, Microvascular Angina diagnosis
Published
2008

29. Endothelial function in patients with chest pain and normal coronary angiograms.

Author

Grabczewska Z, Thews M, Góralczyk K, and Kubica J

Subjects
Aged, Case-Control Studies, Coronary Angiography, Female, Humans, Male, Middle Aged, Chest Pain diagnostic imaging, Chest Pain physiopathology, Endothelium, Vascular physiopathology, Microvascular Angina diagnostic imaging, Microvascular Angina physiopathology
Abstract

Background: A normal coronary angiogram is found in about 20% of patients who undergo coronary angiography due to chest pain. In some of them syndrome X is diagnosed. Endothelial dysfunction is one possible cause of this pathology., Aim: To compare the endothelial function estimated by two different methods in patients with typical or atypical anginal pain and with no chest pain., Methods: Fifty-three patients who underwent coronary angiography due to suspected coronary artery disease and who had a normal coronary angiogram were included in the study: 34 patients had typical anginal pain (group 1) and 19 patients had atypical chest pain (group 2). The control group consisted with 20 subjects without chest pain. The plasma concentration of such endothelial markers as von Willebrand factor (vWF), thrombomodulin (TM), endothelin 1 (ET-1), tissue plasminogen activator (tPA), plasminogen activator inhibitor type 1 (PAI-1) and C-reactive protein were measured. We also determined endothelial-dependent brachial arterial dilatation (flow-mediated dilation, FMD)., Results: The groups of patients were different with regard to the factors of known effects on endothelial function but endothelial markers were not different in all groups with two exceptions. The concentration of tPA was the highest in patients with typical chest pain and the concentration of PAI-1 was the highest in patients without chest pain. The FMD values were low in all patients and there were no significant differences in the FMD values between the three analysed groups. We did not find any correlation between the concentration of examined endothelial markers and FMD. A non-significant relationship between the presence of classical risk factors and decreased FMP was observed. We have found a significant relationship between the number of risk factors and FMD, tPA, PAI-1 and hsCRP., Conclusions: The assessment of endothelial function using FMD or estimation of endothelial markers is not useful to differentiate chest pain.

Published
2007

30. [Acute myocardial infarction in a patient with iatrogenic thyrotoxicosis--a case report].

Author

Grabczewska Z, Białoszyński T, and Kubica J

Subjects
Adult, Coronary Angiography, Creatine Kinase blood, Creatine Kinase, MB Form blood, Electrocardiography, Humans, Male, Myocardial Infarction blood, Myocardial Infarction diagnosis, Myocardial Infarction etiology, Thyrotoxicosis complications, Thyrotropin blood, Thyroxine blood, Triiodothyronine blood, Troponin I blood, Myocardial Infarction diagnostic imaging, Thyrotoxicosis diagnosis
Abstract

We present a patient with myocardial infarction and normal coronary angiogram. The patient had no classical coronary risk factors, but had thyrotoxicosis, which was taken into consideration as a possible cause of myocardial infarction.

Published
2007

31. One-year outcomes of left main coronary artery stenting in patients with cardiogenic shock.

Author

Wiśniewska-Szmyt J, Kubica J, Sukiennik A, Radomski M, Rychter M, Jabłoński M, Białoszyński T, Koziński M, Grabczewska Z, and Grześk G

Abstract

Background: The high in-hospital mortality of patients with cardiogenic shock is being reduced thanks to coronary interventions. The aim of the study was to evaluate the outcomes of angioplasty and stenting in patients with cardiogenic shock caused by left main coronary artery (LMCA) disease., Methods: A group of 71 consecutive patients managed for LMCA disease in an emergency setting (38 patients in cardiogenic shock and 33 without shock symptoms) were followed up clinically and angiographically for one year. Periprocedural and late mortality was assessed as well as the incidence of restenosis and coronary re-interventions., Results: There were 17 deaths in the study population (23.9%). One-year survival in the subgroup with cardiogenic shock was 57.9% (22 patients) with 15 periprocedural deaths and 1 death 3 months after the procedure. Restenosis and associated target lesion revascularization were documented in 5 patients (29.4%) with and 4 patients (16.0%) without cardiogenic shock. Multivariate analysis revealed the following independent predictors of cardiogenic shock in patients undergoing emergency LMCA angioplasty: STEMI as the reason for intervention (OR 14.1; 95% CI 3.71-53.7; p < 0.0002) and a small minimal lumen diameter before the procedure (OR 0.43; 95% CI 0.2-0.93; p < 0.04). The only independent predictor of the death in patients with cardiogenic shock was a small minimal lumen diameter after the procedure (OR 0.31; 95% CI 0.1-0.99, p < 0.05)., Conclusions: High mortality was observed in the study population, especially in the subgroup with cardiogenic shock. Most deaths were periprocedural. Because of the high rate of restenosis, periodical angiographic follow-up is necessary, preferably twice in the first 6 months after stent implantation. (Cardiol J 2007; 14: 67-75).

Published
2007

32. Smokers versus non-smokers undergoing percutaneous transluminal coronary angioplasty: The impact of clinical and procedural characteristics on in-hospital mortality.

Author

Sukiennik A, Koziński M, Debska-Kozińska K, Kubica A, Grabczewska Z, and Kubica J

Abstract

Background: We aimed to compare clinical and procedural characteristics of unselected smokers and non-smokers undergoing percutaneous transluminal coronary angioplasty (PTCA) and to assess their impact on in-hospital mortality., Methods: One thousand consecutive patients treated interventionally were retrospectively enrolled into a single academic centre registry., Results: Smokers (n = 631), in comparison to non-smokers (n = 369), were younger and less likely to be hypertensive, diabetic and female gender. History of myocardial infarction and pre-existing heart failure were also less frequent in the group of smokers. Furthermore, univariate analysis revealed more frequent presentation with acute coronary syndromes (ACS), shorter overall duration of PTCA, shorter exposure to X-rays and lower volume of contrast medium administered in smokers than in non-smokers. Conversely, non-smokers were characterized by considerably higher prevalence of multivessel disease, lower completeness of revascularization and worse final epicardial flow in primary PTCA procedures. Moreover, non-smokers experienced higher crude in-hospital mortality than smokers in the setting of unstable angina/non-ST-segment elevation myocardial infarction (0.0% vs. 6.0%, p = 0.0544) and ST-segment elevation myocardial infarction (6.0% vs. 14.0%, p < 0.02). Smoking status, when adjusted for the baseline characteristics, did not possess any predictive value in terms of in-hospital mortality and surrogates of intervention complexity., Conclusions: A strong trend towards decreased mortality among smokers undergoing PTCA was observed when compared to non-smokers. However, the survival advantage might be fully explained by the younger age of the smokers, their more favourable clinical characteristics and less extensive coronary atherosclerosis. (Cardiol J 2007; 14: 482-492).

Published
2007

33. Endothelial function parameters in patients with unstable angina and infection with Helicobacter pylori and Chlamydia pneumoniae.

Author

Grabczewska Z, Nartowicz E, Kubica J, and Rość D

Abstract

Background: Endothelial dysfunction may be a factor linking infection with atherosclerosis. The aim of our study was to assess the relationship between seropositivity to Helicobacter pylori (Hp) and/or to Chlamydia pneumoniae (Cp) and some endothelial function parameters in patients with unstable angina., Methods: In 31 patients with unstable angina, we determined the serum concentration of the von Willebrand factor (vWF), thrombomodulin, tissue plasminogen activator antigen, and tissue plasminogen activator inhibitor type 1 antigen, the concentration of IgG antibodies to Hp and Cp (all by ELISA), and the level of C-reactive protein. The Western blot test was performed for all patients seropositive to Hp. It allowed us to identify 15 different antigen proteins of Hp., Results: Sixty-one percent of the patients were seropositive to both Hp and Cp, and 35% were seropositive to Hp only. We did not find significant differences in serum concentrations of endothelial function parameters and CRP between the two groups of patients. The patients seropositive to both Hp and Cp had a significantly higher serum concentration of vWF when Hp did not contain the 95 kDa protein (p=0.01) and a significantly higher serum concentration of PAI-1:Ag when Hp did not contain the 57 kDa protein (p=0.002) and the 66 kDa protein (p=0.02)., Conclusion: The results show that the antigenic profile of bacteria may play a more significant role in coronary artery disease than seropositivity.

Published
2006
Full Text
View/download PDF

34. [Recurrent restenosis in patient with single vessel coronary artery disease].

Author

Grabczewska Z, Białoszyński T, Sukiennik A, and Kubica J

Subjects
Female, Humans, Middle Aged, Recurrence, Risk Factors, Coronary Restenosis surgery
Abstract

We present a patient with a single-vessel coronary artery disease, who during 5.5 years underwent 6 coronary intervention procedures -- 3 stent implantations including one drug eluting stent -- TAXUS, 2 balloon coronary angioplasty procedures and CABG. The choice of the optimal therapeutic method in patients with single-vessel coronary artery disease is discussed.

Published
2006

35. Effect of parathormone on heart rate variability in hemodialysis patients.

Author

Polak G, Strózecki P, Grześk G, Manitius J, Grabczewska Z, and Przybył R

Subjects
Adult, Aged, Electrocardiography statistics & numerical data, Female, Heart Rate physiology, Humans, Male, Middle Aged, Regression Analysis, Statistics, Nonparametric, Heart Rate drug effects, Kidney Failure, Chronic physiopathology, Parathyroid Hormone pharmacology, Renal Dialysis statistics & numerical data
Abstract

Introduction: Parathormone (PTH) is a very potent uraemic toxin, which affects heart structure and function. PTH also plays the role in uraemic autonomic neuropathy (AN). The aim of the study was to investigate the relationship between high PTH level and AN assessed with frequency domain measures of heart rate variability (HRV)., Materials and Methods: A 24-h ECG was performed in 40 HD (F=19, M=21) patients aged 49+/-11 years, duration of HD therapy 37+/-30 months. Frequency domain measures of HRV were obtained according to European Society of Cardiology recommendations. Total spectral power (TP), high frequency band (HF) and low frequency band (LF) were computed as indexes of: total autonomic nervous system (ANS) activity, parasympathetic and sympathetic activities, respectively. LF/HF ratio was calculated. TP, HF, LF and LF/HF were expressed as natural logarithm. Patients were divided into two groups due to PTH level: PTH+ (PTH> or =275 pg/ml) and PTH- (PTH<275 pg/ml)., Results: The values of lnTP and lnLF were lower in patients PTH+ than in patients PTH- (6,58+/-0,76 vs. 6,99+/-0,44 ms2, p<0,05, and 4,91+/-0,99 vs. 5,33+/-0,65 ms2, respectively, p=0,06). We also found negative correlation between lnPTH and lnTP (r=-0,47; p<0,005), lnPTH and lnLF (r=-0,35; p<0,05), lnPTH and lnHF (r=-0,34; p<0,05). On multiple regression analysis, lnTP, lnLF and lnHF were independently related to lnPTH., Conclusions: Parathormone exerts effect on activity of both parts of autonomic nervous system: sympathetic and parasympathetic. High PTH level deteriorates total autonomic activity.

Published
2004
Full Text
View/download PDF

36. Myocardial infarction with normal coronary arteriogram: the role of ephedrine-like alkaloids.

Author

Grześk G, Polak G, Grabczewska Z, and Kubica J

Subjects
Adult, Coronary Angiography, Electrocardiography, Ephedrine therapeutic use, Humans, Male, Myocardial Infarction diagnostic imaging, Ephedrine adverse effects, Myocardial Infarction chemically induced, Respiratory Tract Infections drug therapy, Smoking adverse effects
Abstract

Background: The overwhelming majority of myocardial infarctions result from atherosclerosis, generally with superimposed coronary thrombosis. The prevalence of patients who develop myocardial infarction and in whom subsequent angiography shows normal coronary arteries is approximately 5%. Many of these cases are caused by coronary artery spasm and/or thrombosis, perhaps with an underlying endothelial dysfunction of the epicardial coronary arteries., Case Report: The authors present a case of acute myocardial infarction with normal coronary arteriogram which occurred in a 19-year-old, cigarette-smoking male following usage of a pseudoephedrine-containing drug for an upper respiratory tract infection. Coronary artery spasm, associated with taking pseudoephedrine, and a prothrombotic state, related to the platelet and endothelial effects of cigarette smoking and infection, were the possible mechanisms of myocardial infarction in the reported case., Conclusions: A diagnosis of acute myocardial infarction should be seriously considered even in relatively young tobacco-smoking patients, especially after acute alcohol intoxication or cocaine, amphetamine or ephedrine exposure. It is very important to obtain a complete history of the use of such 'safe' drugs, which do not need to be administered by a doctor but may contain treacherous components. These data provide the necessary background for making an accurate diagnosis and appropriate decisions concerning therapy.

Published
2004

37. [Acute myocardial infarction in a patient with normal coronary arteries--a case report].

Author

Grabczewska Z, Dybowski J, Sukiennik A, Kubica J, and Wrabec K

Subjects
Aged, Coronary Angiography, Electrocardiography, Female, Humans, Myocardial Infarction diagnosis, Myocardial Infarction diagnostic imaging, Myocardial Infarction physiopathology, Coronary Vessels, Myocardial Infarction etiology, Pacemaker, Artificial adverse effects
Abstract

A case of a 72-year-old female who was admitted for elective dual-chamber pacemaker implantation, is presented. A few hours after the procedure the patient developed chest pain with ST-segment elevation in ECG and a significant increase in the troponin I level. An acute myocardial infarction was diagnosed. Urgent coronary angiography revealed normal coronary arteries without spasm. Possible causes of acute myocardial infarction following pacemaker implantation are discussed.

Published
2004

38. [Yawning as a prodromal sign of vaso-vagal reaction].

Author

Grabczewska Z, Orzałkiewicz Z, Przybył R, Polak G, Grześk G, and Nartowicz E

Subjects
Blood Vessels innervation, Bradycardia physiopathology, Cardiac Surgical Procedures, Humans, Muscle Hypotonia physiopathology, Reflex, Blood Vessels physiopathology, Vagus Nerve physiopathology, Yawning
Published
2003

39. [Cardiac tamponade as a cause for exploratory laparatomy - a case report].

Author

Nartowicz E, Grabczewska Z, and Wodyńska T

Subjects
Abdomen, Acute diagnosis, Abdomen, Acute etiology, Abdomen, Acute surgery, Adult, Cardiac Tamponade complications, Cardiac Tamponade surgery, Diagnosis, Differential, Echocardiography, Electrocardiography, Heart Neoplasms physiopathology, Humans, Male, Pericardiocentesis, Time Factors, Treatment Outcome, Cardiac Tamponade diagnosis, Heart Neoplasms complications, Laparotomy
Abstract

We present a case of 39-year-old male with symptomatic cardiac tamponade due to neoplastic disease. Because of abdominal symptoms the patient was diagnosed as having acute abdomen and underwent exploratory laparatomy which revealed enlarged liver and ascites. Correct diagnosis was established later by echocardiography and effective pericardiocentesis was performed. Diagnostic difficulties in patients with cardiac tamponade are discussed.

Published
2003

40. [Coronary artery stenting in the treatment of 5-fluorouracil-induced unstable angina].

Author

Grześk G, Orzałkiewicz Z, Polak G, Przybył R, Nartowicz E, Szadujkis-Szadurski L, and Grabczewska Z

Subjects
Angina Pectoris diagnostic imaging, Antimetabolites, Antineoplastic administration & dosage, Colonic Neoplasms drug therapy, Coronary Angiography, Dose-Response Relationship, Drug, Drug Administration Schedule, Electrocardiography, Female, Fluorouracil administration & dosage, Heart drug effects, Heart physiopathology, Humans, Middle Aged, Time Factors, Treatment Outcome, Angina Pectoris chemically induced, Angina Pectoris therapy, Antimetabolites, Antineoplastic adverse effects, Fluorouracil adverse effects, Stents
Abstract

Cardiotoxicity is a rare but very serious side effect of 5-fluorouracil (5-FU) treatment. Many theories have been suggested to explain the mechanism of this problem. Most commonly, coronary artery spasm is considered responsible in cardiovascular toxicity. Ischemic symptoms and signs related to 5-FU therapy are observed during the late phase of the administration of the drug. The close and careful monitoring of all patients, especially the ones with pre-existent coronary artery disease, during 5-FU infusion is mandatory. Because there is not a single and effective modality of prevention of 5-FU cardiotoxicity, the patients should be selected carefully for its administration, 5-FU infusion should be stopped as soon as symptoms are encountered. A case of a 58-year-old woman treated with 5-FU due to colon cancer is described. In the late phase of 5-FU administration, the patient developed anginal pain with transitional ST segment elevation in ECG. Patient, after coronary angiography, was successfully treated with percutaneous coronary intervention. Interventional methods, most of all stent implantation, seem to be the best treatment of 5-FU-related acute coronary syndromes.

Published
2003

41. Endothelial dysfunction in acute coronary syndrome without ST segment elevation in the presence of Helicobacter pylori infection.

Author

Grabczewska Z, Nartowicz E, Szymaniak L, Wiśniewska E, Przybył R, Polak G, Kubica J, Dymek G, Giedrys-Kalemba S, Kotschy M, and Odrowaz-Sypniewska G

Abstract

Background: Helicobacter pylori (H. pylori) infection is one of the most common chronic infections in humans. While a causative relationship between H. pylori infection and several gastrointestinal disorders has been well established, the association between this condition and the development of atherosclerosis and coronary artery diseases (CAD) is less clear., Aim: To examine the relationship between H. pylori infection and endothelial function in patients with acute coronary syndrome (ACS) without ST segment elevation., Methods: The study group consisted of 31 patients (17 males aged 38-78 years and 14 females aged 45-80 years) with ACS and without ST segment elevation in whom we measured antibodies to H. pylori and haemostatic factors indicating endothelial function, such as von Willebrand factor (vWF), thrombomodulin (TM), tissue plasmin activator (tPA:Ag), tPA inhibitor (PAI-1:Ag) and fibrinogen., Results: The proportion of patients with H. pylori seropositivity was 93.5%. No significant relationship between parameters of endothelial function and IgG antibodies to H. pylori were found. There was a significant association between antibodies to p54 protein and vWF (p=0.027) and between antibodies to p33 protein and PAI:Ag concentration (p=0.019)., Conclusions: These results suggest that the type of H. pylori antigens and antibodies to these antigens rather than the presence of IgG antibodies to H. pylori may play a role in the development of CAD.

Published
2002

42. Antibodies to Chlamydia pneumoniae and haemostatic factors in acute coronary syndrome without ST segment elevation.

Author

Grabczewska Z, Nartowicz E, Szymaniak L, Wiśniewska E, Wodyńska T, Przybył R, Dymek G, Kubica J, Giedrys-Kalemba S, Kotschy M, and Odrowaz-Sypniewska G

Abstract

Background: Various chronic infections, including Chlamydia pneumoniae (C. pneumoniae), are regarded as one of the possible factors which initiates, progresses and exacerbates atherosclerotic process. The relationship between C. pneumoniae infection and haemostatic factors which also may promote atherosclerosis, has not yet been established., Aim: To assess the relationship between C. pneumoniae-specific IgA and IgG serum antibodies and haemostatic factors in patients with acute coronary syndrome (ACS)., Methods: The study group consisted of 31 patients (17 males, mean age 62 years, and 14 females, mean age 60.6 years) with ACS and without ST segment elevation in whom antibodies to C. pneumoniae and such haemostatic factors as von Willebrand factor (vWF), thrombomodulin (TM), tissue plasmin activator (tPA), tPA inhibitor (PAI-1) and fibrinogen were measured., Results: The proportion of patients with C. pneumoniae seropositivity was 35.4% in our study which is lower than that reported in literature. No significant relationship between vWF, TM, tPA and PAI-1 levels, and C. pneumoniae infection was found whereas a significant (p=0.05) relationship between C. pneumoniae-specific IgG antibodies and fibrinogen level was detected., Conclusions: Excluding fibrinogen, the presence of antibodies to C. pneumoniae is not associated with increased levels of haemostatic factors in patients with ACS without ST segment elevation.

Published
2002

43. [Incomplete percutaneous coronary revascularization in 82-year-old patient with chronic renal failure and neoplastic disease. Case report].

Author

Przybył R, Orzałkiewicz Z, Grabczewska Z, Polak G, Grześk G, and Nartowicz E

Subjects
Aged, Aged, 80 and over, Angina Pectoris diagnosis, Electrocardiography, Humans, Male, Severity of Illness Index, Angina Pectoris complications, Angina Pectoris surgery, Angioplasty, Balloon, Coronary instrumentation, Kidney Failure, Chronic complications, Kidney Neoplasms complications
Abstract

We report a case of octogenarian with pharmacotherapy resistant angina pectoris, who was successfully treated by percutaneous coronary intervention.

Published
2002

44. [Retrospective analysis of prognostic factors for annual mortality in 97 patients with chronic congestive heart failure].

Author

Bogdan M, Nartowicz E, and Grabczewska Z

Subjects
Adult, Aged, Chronic Disease, Disease Progression, Female, Humans, Male, Middle Aged, Prognosis, Retrospective Studies, Heart Failure mortality
Abstract

The aim of our study was to find clinical and biochemical factors, which are prognostically important for the annual mortality in patients with chronic congestive heart failure (CHF). The studied group consisted of 97 people with CHF (31 females and 66 males, mean age--61). The causes of the heart failure were: coronary artery disease or/and hypertension (80 patients), valvular mitral heart disease--(12 patients), dilated cardiomyopathy--(5 patients). On the first day of the hospitalization patients were classified as functional class II-IV according to NYHA classification. Patients were divided into: group 'A'--34 patients, who had died during the 1st year of observation, and group 'B'--63 patients who have survived the 1st year of observation. According to the results of our study patients from group A had lower concentration of plasma sodium, lower left ventricular ejection fraction, lower mean heart rate, higher frequency of ventricular arrhythmias (according to 3&4 Lown class).

Published
2000

45. [Hyponatremia in congestive heart failure].

Author

Bogdan M, Grabczewska Z, and Nartowicz E

Subjects
Heart Failure drug therapy, Heart Failure metabolism, Humans, Hyponatremia drug therapy, Hyponatremia metabolism, Heart Failure complications, Hyponatremia complications
Published
1999

46. [Infections with Chlamydia pneumoniae, Helicobacter pylori or cytomegalovirus and atherosclerosis].

Author

Grabczewska Z and Nartowicz E

Subjects
Anti-Bacterial Agents therapeutic use, Chlamydia Infections diagnosis, Chlamydia Infections drug therapy, Chlamydia Infections epidemiology, Comorbidity, Coronary Artery Disease epidemiology, Coronary Artery Disease prevention & control, Cytomegalovirus Infections diagnosis, Cytomegalovirus Infections drug therapy, Cytomegalovirus Infections epidemiology, Disease Progression, Helicobacter Infections diagnosis, Helicobacter Infections drug therapy, Helicobacter Infections epidemiology, Humans, Prevalence, Chlamydia Infections complications, Chlamydophila pneumoniae, Coronary Artery Disease microbiology, Cytomegalovirus Infections complications, Helicobacter Infections complications, Helicobacter pylori
Abstract

It's known that common risk factors of atherosclerosis can explain only 50% of its etiology. In only 40% patients risk factors modification inhibits progression of atherosclerosis. Therefore looking for new risk factors of atherosclerosis is necessary. In recent years the inflammatory-infectious hypothesis of atherosclerosis has been reevaluated. The discovery of heavy infections load in the serum of patients with acute coronary syndromes might suggest a potential immunological mechanism triggered by bacterial proteins. Chlamydia pneumoniae, Helicobacter pylori and cytomegalovirus infections are very common in human population and therefore they are suspected as the main infectious pathogen in the coronary disease. Clinical studies have demonstrated higher anti-Chlamydia and ani-Helicobacter antibody titres in patients with myocardial infarction (60-70% pts), stable and unstable angina (50-60% pts) than in control groups (12-15% pts). Two studies were performed with antibiotic (azotromycin, roxitromycin) influence on the prevalence of acute coronary syndromes after myocardial infarction and unstable angina. These studies have shown statistically significant reduction of the prevalence of acute coronary episodes in follow-up period.

Published
1999

47. [The heart in arterial hypertension].

Author

Grabczewska Z and Nartowicz E

Subjects
Cardiomegaly etiology, Cardiomegaly prevention & control, Collagen physiology, Hemodynamics physiology, Humans, Heart physiopathology, Hypertension physiopathology
Abstract

The data is presented on the pathogenesis of myocardial changes in arterial hypertension. The non-haemodynamic causes are discussed of myocardial hypertrophy, as well as the participation of collagen in its early phase and the haemodynamic consequences of hypertrophy and its regression. Hypotensive drugs and their ability ot prevent myocardial hypertrophy and (or) inducing of its regression were compared.

Published
1992

Catalog

Books, media, physical & digital resources
See catalog results